trial · primary record
MORAb-202
Neoplasms, Ovarian
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 106 |
| Primary completion | 2025-09-10 |
| Primary endpoint | Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment |
| Registry ID | NCT05613088 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:44:05.863Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05613088
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.